Bulletin
Investor Alert

New York Markets Close in:

Edwards Lifesciences Corp.

NYS: EW

GO
/marketstate/country/us

Market open

 --Real time quotes

Jul 9, 2020, 2:34 p.m.

EW
/zigman2/quotes/205745196/composite

$

68.25

Change

-0.51 -0.74%

Volume

Volume 1.24m

Real time quotes

/zigman2/quotes/205745196/composite

Previous close

$ 68.76

$ 68.25

Change

-0.51 -0.74%

Day low

Day high

$67.27

$69.23

Open

52 week low

52 week high

$51.51

$82.55

Open

Company Description

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes tech...

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Valuation

P/E Current

41.81

P/E Ratio (with extraordinary items)

39.42

P/E Ratio (without extraordinary items)

47.29

Price to Sales Ratio

11.39

Price to Book Ratio

11.76

Price to Cash Flow Ratio

41.97

Enterprise Value to EBITDA

37.01

Enterprise Value to Sales

11.19

Total Debt to Enterprise Value

0.01

Efficiency

Revenue/Employee

312,806.00

Income Per Employee

75,317.00

Receivables Turnover

7.65

Total Asset Turnover

0.74

Liquidity

Current Ratio

3.31

Quick Ratio

2.60

Cash Ratio

1.68

Profitability

Gross Margin

73.43

Operating Margin

27.55

Pretax Margin

26.83

Net Margin

24.08

Return on Assets

17.73

Return on Equity

28.73

Return on Total Capital

27.98

Return on Invested Capital

24.53

Capital Structure

Total Debt to Total Equity

16.36

Total Debt to Total Capital

14.06

Total Debt to Total Assets

10.46

Long-Term Debt to Equity

15.75

Long-Term Debt to Total Capital

13.53

Officers and Executives

Name Age Officer Since Title
Mr. Michael A. Mussallem 66 2000 Chairman & Chief Executive Officer
Mr. Scott B. Ullem 52 2014 Chief Financial Officer & Vice President
Dr. John P. McGrath 59 2006 Vice President-Quality, Regulatory & Clinical
Dr. Todd J. Brinton - 2019 Chief Scientific Officer & VP-Advanced Technology
Mr. Larry L. Wood 53 1985 Vice President-Transcatheter Aortic Valve

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
07/06/2020 Scott B. Ullem
CVP, Chief Financial Officer
26,700   Disposition at $69.98 per share. 1,868,466
07/06/2020 Huimin Wang
CVP, Japan & Intercontinental
591   Disposition at $70 per share. 41,370
07/06/2020 Scott B. Ullem
CVP, Chief Financial Officer
26,700   Derivative/Non-derivative trans. at $13.98 per share. 373,266
07/01/2020 Larry L. Wood
CVP, TAVR
9,393   Disposition at $68.82 per share. 646,426
07/01/2020 Larry L. Wood
CVP, TAVR
1,305   Disposition at $69.47 per share. 90,658
07/01/2020 Larry L. Wood
CVP, TAVR
10,698   Derivative/Non-derivative trans. at $21.76 per share. 232,788
06/22/2020 Scott B. Ullem
CVP, Chief Financial Officer
24,479   Disposition at $69.45 per share. 1,700,066
06/22/2020 Scott B. Ullem
CVP, Chief Financial Officer
2,221   Disposition at $70.19 per share. 155,891
06/22/2020 Scott B. Ullem
CVP, Chief Financial Officer
26,700   Derivative/Non-derivative trans. at $13.98 per share. 373,266
06/16/2020 Catherine M. Szyman
CVP, Critical Care
3,348   Disposition at $70.67 per share. 236,603
06/15/2020 Michael A. Mussallem
Chairman & CEO; Director
30,000   Gift at $0 per share. 0
06/15/2020 Michael A. Mussallem
Chairman & CEO; Director
98,550   Derivative/Non-derivative trans. at $13.98 per share. 1,377,729
06/15/2020 Michael A. Mussallem
Chairman & CEO; Director
30,000   Gift at $0 per share. 0
06/15/2020 Michael A. Mussallem
Chairman & CEO; Director
37,312   Disposition at $68.81 per share. 2,567,438
06/15/2020 Michael A. Mussallem
Chairman & CEO; Director
21,938   Disposition at $67.65 per share. 1,484,105
06/15/2020 Michael A. Mussallem
Chairman & CEO; Director
6,200   Disposition at $66.91 per share. 414,842
06/15/2020 Michael A. Mussallem
Chairman & CEO; Director
3,100   Disposition at $69 per share. 213,900
06/12/2020 Donald E. Bobo
CVP,Strategy/Corp Development
13,074   Disposition at $69.86 per share. 913,349
06/12/2020 Donald E. Bobo
CVP,Strategy/Corp Development
13,074   Derivative/Non-derivative trans. at $13.98 per share. 182,774
06/11/2020 Huimin Wang
CVP, Japan & Intercontinental
8,362   Disposition at $71.25 per share. 595,792
06/11/2020 Huimin Wang
CVP, Japan & Intercontinental
3,287   Disposition at $72.42 per share. 238,044
06/11/2020 Huimin Wang
CVP, Japan & Intercontinental
84   Disposition at $72.59 per share. 6,097
06/11/2020 Catherine M. Szyman
CVP, Critical Care
2,249   Disposition at $72.59 per share. 163,254
06/11/2020 Huimin Wang
CVP, Japan & Intercontinental
11,649   Derivative/Non-derivative trans. at $13.98 per share. 162,853
06/01/2020 Larry L. Wood
CVP, TAVR
10,698   Disposition at $75.3 per share. 805,559
06/01/2020 Larry L. Wood
CVP, TAVR
10,698   Derivative/Non-derivative trans. at $21.76 per share. 232,788
05/29/2020 Scott B. Ullem
CVP, Chief Financial Officer
14,487   Gift at $0 per share. 0
05/29/2020 Scott B. Ullem
CVP, Chief Financial Officer
14,487   Gift at $0 per share. 0
05/18/2020 Huimin Wang
CVP, Japan & Intercontinental
1,717   Disposition at $216.68 per share. 372,039
/news/latest/company/us/ew

MarketWatch News on EW

  1. The Dow Is Dropping. Just Don’t Call It a Bad Day.

    2:19 p.m. June 4, 2020

    - Barron's Online

  2. Edwards Lifesciences upgraded to outperform from market perform at SVB Leerink

    6:44 a.m. April 17, 2020

    - Tomi Kilgore

  3. Edwards Lifesciences stock price target cut to $230 from $263 at Raymond James

    7:51 a.m. April 9, 2020

    - Tomi Kilgore

  4. Edwards Lifesciences started at outperform with $280 stock price target at Oppenheimer

    9:52 a.m. Jan. 10, 2020

    - Tomi Kilgore

  5. Edwards Lifesciences stock price target raised to $263 from $255 at Raymond James

    8:40 a.m. Dec. 6, 2019

    - Tomi Kilgore

  6. Edwards Lifesciences stock price target raised to $275 from $250 at Stifel Nicolaus

    8:26 a.m. Dec. 6, 2019

    - Tomi Kilgore

  7. The 3 Best-Performing Health Care Stocks of 2019 So Far

    8:30 a.m. Nov. 28, 2019

    - Barron's Online

  8. Edwards Lifesciences stock price target raised to $250 from $215 at Stifel Nicolaus

    8:17 a.m. Oct. 24, 2019

    - Tomi Kilgore

  9. The Dow Is Up, but This Week Is All About Federal Reserve Signals

    12:36 p.m. Aug. 22, 2019

    - Barron's Online

  10. Edwards Stock Is Soaring, but Analysts Remain Wary

    1:59 p.m. July 24, 2019

    - Barron's Online

  11. Snap Stock Soars, UPS Jumps as Dow Jones Industrial Average Drops

    12:35 p.m. July 24, 2019

    - Barron's Online

  12. Edwards Lifesciences stock price target raised to $225 from $215 at BofA Merrill Lynch

    9:34 a.m. July 24, 2019

    - Tomi Kilgore

  13. Edwards Lifesciences shares jump after earnings

    4:34 p.m. July 23, 2019

    - MarketWatch.com

  14. Loading more headlines...
/news/nonmarketwatch/company/us/ew

Other News on EW

  1. Buy And Hold Vs. Rotational Strategy: June 2020 Update

    4:29 p.m. July 7, 2020

    - Seeking Alpha

  2. Abiiomed: Lots Of Growth Ahead

    1:08 p.m. July 6, 2020

    - Seeking Alpha

  3. Edwards Lifesciences (EW) Receives a Hold from BTIG

    4:29 p.m. June 18, 2020

    - SmarterAnalyst

  4. Tailoring Portfolios to Coronavirus and Recession

    8:41 a.m. June 8, 2020

    - GuruFocus.com

  5. Buy And Hold Vs. Rotational Strategy: May 2020 Update

    2:36 p.m. June 2, 2020

    - Seeking Alpha

  6. EVH, PFE among premarket losers

    9:21 a.m. June 1, 2020

    - Seeking Alpha

  7. IPO Update: Inari Medical Proposes IPO Terms

    2:15 p.m. May 18, 2020

    - Seeking Alpha

  8. Wedgewood Partners Cuts Fastenal, Alphabet, Visa

    11:07 a.m. May 18, 2020

    - GuruFocus.com

  9. Buy-And-Hold Vs. Rotational Strategy April 2020 Update

    1:52 a.m. May 6, 2020

    - Seeking Alpha

  10. Loading more headlines...

At a Glance

Edwards Lifesciences Corp.

One Edwards Way

Irvine, California 92614

Phone

1 9492502500

Industry

Medical Equipment/Supplies

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$4.35B

Net Income

$1.05B

2019 Sales Growth

16.8%

Employees

13,900

/news/pressrelease/company/us/ew

Press Releases on EW

  1. Edwards Lifesciences To Host Earnings Conference Call On July 23, 2020

    10:05 a.m. Today

    - PR Newswire - PRF

  2. Transcatheter Devices Market Worth Nearly $19.4 Bn by 2026

    7:54 a.m. July 8, 2020

    - Global QYResearch

  3. Loading more headlines...
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.